BRISBANE, Calif. and SHANGHAI, June 17,
2024 /PRNewswire/ -- ReviR
Therapeutics, a biotechnology company specializing in the
development of small molecule RNA splicing modulators for
neurogenetic diseases and oncology indications, and Asieris
Pharmaceuticals, a global biopharmaceutical leader in the
discovery, development, and commercialization of innovative drugs
for genitourinary tumors and related diseases, announced a
milestone was reached today in their ongoing collaboration. The
joint effort to develop treatments for cancers using a novel target
has resulted in the successful identification of a new lead series
of small molecules that modulate the expression of an oncogenic
driver gene. The molecules were discovered using ReviR's
proprietary VoyageR AI platform which has the potential to
revolutionize therapeutic discovery across multiple indications,
including genitourinary cancers.
The collaboration successfully completed the first milestone of
target engagement, and demonstrated that a series of molecules from
ReviR's proprietary compound library are capable of driving
inclusion of a cryptic exon into the mRNA of a novel target gene,
thus resulting in subsequent reduction of the disease protein. This
discovery advances the development of a novel therapy for
genitourinary cancers one step closer to clinical development.
ReviR's VoyageR AI platform offers significant advantages to
characterize small molecule splicing modulators, including target
identification as well as enhanced potency and specificity
assessments across genomes. This platform holds immense promise for
the development of novel treatments for a broad spectrum of genetic
diseases including Huntington's Disease, which is a key focus for
ReviR's pipeline development.
"We are very pleased with what our team, alongside our esteemed
collaborators at ReviR Therapeutics, has accomplished. This
milestone demonstrates the value of teamwork in accelerating
advancements in drug discovery," said Alice
Chen, Senior Vice President of Discovery Biology & Head
of Translational Research at Asieris Pharmaceuticals.
Peng Yue, PhD, CEO of ReviR
Therapeutics, said, "Today marks a significant milestone in our
journey to develop a new therapy for cancers with limited treatment
options. This breakthrough in splicing modulator technology brings
us one step closer to bringing much-needed relief to patients."
Both companies are evaluating the option to further discover and
develop novel small molecule splicing modulators towards novel
targets and exploring the potential of expanding VoyageR to various
therapeutic applications. This collaboration exemplifies the power
of joint efforts in driving innovation within the field of splicing
modulators and paving the way for a future with more effective
treatments for genetic diseases and targeted oncology
therapies.
About Asieris Pharmaceuticals
Founded in March 2010, Asieris
Pharmaceuticals (Stock Code: 688176.SH) is a global
biopharmaceutical company committed to the discovery, development,
and commercialization of innovative drugs for the treatment of
genitourinary tumors and related diseases. Our mission is to
enhance human health and uphold patient dignity. We aspire to be a
global pharmaceutical leader, integrating research and development
(R&D), manufacturing, and commercialization to deliver
top-tier, integrated diagnostic and treatment solutions for
patients both in China and around
the world.
Asieris has been advancing its proprietary R&D platform and
core technologies, pioneering new mechanisms of action, and
conducting efficient screening and evaluation of drug candidates.
With a robust in-house R&D system and a wealth of expertise in
global drug development, we are dedicated to introducing
first-in-class drugs and innovative products, addressing
significant unmet medical needs in our areas of specialization.
In our pursuit of excellence in treating genitourinary diseases,
Asieris actively enhances its pipeline through proprietary R&D
endeavors and strategic partnerships. We remain at the forefront of
emerging technologies and therapeutic advances. Our approach is
both proactive and forward-thinking, focusing on identifying and
addressing unmet clinical needs. We aim to develop an exceptional
portfolio encompassing both diagnosis and treatment, striving to
improve the lives of more patients in China and across the globe.
About ReviR Therapeutics
ReviR Therapeutics is an emerging biopharmaceutical company
focused on the development of RNA-targeting small molecule
therapies that modulate the causal genes of diseases, including CNS
diseases, cancer, and other rare genetically-defined diseases. The
company is utilizing cutting-edge technologies to develop therapies
with the goal of developing disease modifying therapies that are
efficacious, safe, and specific. The company's initial focus is to
apply SpliceR modulation technologies towards RNA targets of
genetic diseases with limited or no treatment options. ReviR
Therapeutics was founded in 2021 by leaders in computational
biology, AI/ML, RNA biology, and drug discovery. The company is
headquartered in Brisbane, CA. For
more information, visit our website www.revirtx.com or email
info@revirtx.com.
View original
content:https://www.prnewswire.com/news-releases/revir-therapeutics-reaches-milestone-in-novel-splicing-therapy-development-in-collaboration-with-asieris-pharmaceuticals-302171821.html
SOURCE ReviR Therapeutics